State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, National Institute of Diagnostics and Vaccine Development in Infectious Diseases, Strait Collaborative Innovation Center of Biomedicine and Pharmaceutics, School of Public Health, Xiamen University.
Liuzhou Center for Disease Control and Prevention, China.
Clin Infect Dis. 2020 Jan 1;70(1):82-89. doi: 10.1093/cid/ciz168.
Human papillomavirus (HPV) causes anogenital warts and cancers in men and women. However, little is known about sex differences regarding the natural history of anogenital HPV infection.
Starting in May 2014, an observational cohort study including 2309 men and 2378 women aged 18-55 years was conducted in Liuzhou, China. Samples from anogenital sites were tested for HPV genotypes by multicolor real-time polymerase chain reaction and melting curve analysis biannually for ~1 year.
The incidence of oncogenic HPV infection was similar in men and women (10.3 and 11.5/1000 person-months; P = .275), whereas the incidence of HPV-6/11 infection was higher in men than in women (2.0 vs 1.1; P = .018). The incidence of both oncogenic HPV and HPV-6/11 infections was significantly higher in women in the 18- to 25-year age group than in the older age groups (P = .006 and .011, respectively), whereas it did not vary by age among men (P = .552 and .425, respectively). Additionally, men were more likely than women to clear oncogenic infections (101.5 vs 58.6/1000 person-months; P < .001), but no significant difference was found in the clearance of HPV-6/11 by sex (111.7 vs 84.8; P = .266). The median time to clearance of oncogenic type and type 6/11 infections was not age dependent for either sex (all P > .05).
The natural history of oncogenic and nononcogenic HPV infection differs by sex, which implies that sex-specific vaccination strategies should be considered for oncogenic and nononcogenic HPV.
NCT02188004.
人乳头瘤病毒(HPV)可导致男性和女性的肛门生殖器疣和癌症。然而,关于肛门生殖器 HPV 感染的自然史,人们对性别差异知之甚少。
从 2014 年 5 月开始,在中国柳州对 2309 名 18-55 岁的男性和 2378 名女性进行了一项观察性队列研究。每 6 个月用多色实时聚合酶链反应和熔解曲线分析对肛门生殖器部位的样本进行 HPV 基因型检测,持续约 1 年。
男性和女性的致癌 HPV 感染发生率相似(10.3 和 11.5/1000 人-月;P=0.275),而 HPV-6/11 感染的发生率男性高于女性(2.0 比 1.1;P=0.018)。18-25 岁年龄组女性的致癌 HPV 和 HPV-6/11 感染发生率均显著高于年龄较大的组(P=0.006 和 0.011),而男性的感染发生率则无年龄差异(P=0.552 和 0.425)。此外,男性清除致癌感染的可能性高于女性(101.5 比 58.6/1000 人-月;P<0.001),但男女之间 HPV-6/11 的清除率无显著差异(111.7 比 84.8;P=0.266)。性别的致癌和非致癌 HPV 感染的清除中位时间与年龄无关(所有 P>0.05)。
致癌和非致癌 HPV 感染的自然史因性别而异,这意味着应考虑针对致癌和非致癌 HPV 的性别特异性疫苗接种策略。
NCT02188004。